InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research note published on Saturday. The brokerage issued a sell rating on the stock.

A number of other brokerages have also recently commented on NSPR. Piper Sandler reaffirmed an “overweight” rating and set a $4.50 target price on shares of InspireMD in a report on Tuesday, September 17th. Lake Street Capital assumed coverage on InspireMD in a research note on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective for the company.

InspireMD Stock Down 6.3 %

Shares of NYSE NSPR opened at $2.69 on Friday. The company has a market cap of $70.17 million, a P/E ratio of -3.59 and a beta of 0.98. InspireMD has a 52 week low of $1.81 and a 52 week high of $3.42. The business has a 50-day simple moving average of $2.73 and a two-hundred day simple moving average of $2.70.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. During the same quarter last year, the company earned ($0.15) EPS. Equities research analysts anticipate that InspireMD will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in InspireMD stock. Affiance Financial LLC acquired a new stake in InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned about 0.74% of InspireMD as of its most recent SEC filing. 44.78% of the stock is currently owned by institutional investors and hedge funds.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.